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pituitary–adrenal (HPA) axis plays a protective role in the body’s defence against sepsis.
Sepsis induces a profound systemic immune response and cytokines serve as excellent
markers for sepsis as they act as mediators of the immune response. Evidence suggests that
the adipokine leptin may play a pathogenic role in sepsis. Mouse endotoxaemic models
present with elevated leptin levels and exogenously added leptin increased mortality
whereas human septic patients have elevated circulating levels of the soluble leptin receptor
(Ob-Re). Evidence suggests that leptin can inhibit the regulation of the HPA axis. Thus, leptin
may suppress the HPA axis, impairing its protective role in sepsis. We hypothesised that leptin
would attenuate the HPA axis response to sepsis. We investigated the direct effects of an i.p.
injection of 2 mg/kg leptin on the HPA axis response to intraperitoneally injected 25 mg/kg
lipopolysaccharide (LPS) in the male Wistar rat. We found that LPS potently activated the
HPA axis, as shown by significantly increased plasma stress hormones, ACTH and
corticosterone, and increased plasma interleukin 1b (IL1b) levels, 2 h after administration.
Pre-treatment with leptin, 2 h before LPS administration, did not influence the HPA axis
response to LPS. In turn, LPS did not affect plasma leptin levels. Our findings suggest that
leptin does not influence HPA function or IL1b secretion in a rat model of LPS-induced sepsis,
and thus that leptin is unlikely to be involved in the acute-phase endocrine response to
bacterial infection in rats.Key Words
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.0 UJournal of Endocrinology
(2014) 221, 237–242IntroductionSepsis is the result of an over-activation of the innate
immune response against bacterial infections (Matot &
Sprung 2001) and can result in fever, tachypnea, tachy-
cardia, deregulated organ perfusion, renal failure,hypoxaemia and altered mental state (Bone et al. 1989).
Biomarkers of sepsis include cytokines such as inter-
leukin 1B (IL1b; Sankar & Webster 2012), as well as other
receptor and cell marker biomarkers (Heuer et al. 2004).sed under a Creative Commons
nported License.
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221 :2 238Sepsis progression can result in immune dysfunction
(Tschop et al. 2010), which is the leading cause for
mortality in non-coronary patients in non-Western
countries (Arabi et al. 2003), comparable with annual
death rates from acute myocardial infarction in Western
countries. Obesity is a risk factor for sepsis morbidity and
mortality. Morbid obesity increases the risk of death by
sepsis following major surgery by 50% (Prabhakar et al.
2002). It is thought that the pro-inflammatory phenotype
that accompanies obesity creates a context in which any
additional inflammatory stimulus results in an exagger-
ated inflammatory response (Vachharajani 2008).
The adipose tissue-derived hormone leptin has a well-
characterised role in energy homoeostasis, but has also
been suggested to play a pathogenic role in sepsis (Shapiro
et al. 2010). Mouse endotoxaemia and caecal ligation
puncture models of sepsis present with elevated levels of
leptin, while exogenous administration of leptin to
endotoxaemic mice increases mortality (Shapiro et al.
2010). Human septic patients have elevated circulating
levels of the soluble leptin receptor (Ob-Re), which
correlate with disease severity indices (Shapiro et al.
2010). Leptin has been reported to serve as an early
biomarker of sepsis in patients, allowing differentiation
between patients with systemic inflammatory response
syndrome and patients with sepsis (Yousef et al. 2010). The
hypothalamic–pituitary–adrenal (HPA) axis plays an
important protective role in the body’s defence against
sepsis during a bacterial infection. Bacterial proteins
stimulate the release of cytokines, including tumour
necrosis factor a (TNFa), IL1 and IL6 (John & Buckingham
2003), which can modulate the HPA axis increasing
expression of corticotrophin-releasing hormone (CRH)
and arginine vasopressin in the hypothalamus, and
adrenocorticotropic hormone (ACTH) in the pituitary
gland (John & Buckingham 2003) and increasing
circulating glucocorticoid levels (Besedovsky et al. 1986).
Glucocorticoids themselves act in a negative feedback
loop to suppress the HPA axis, leading to a shift from pro-
inflammatory immune responses to anti-inflammatory
immune responses (Elenkov & Chrousos 1999). There is
evidence to suggest that leptin has an inhibitory role in
the regulation of the HPA axis (Maffei et al. 1995). Leptin
administrationblunts the restraint stress-inducedactivation
of the HPA axis in mice (Heiman et al. 1997) and can
directly inhibit ACTH-stimulated cortisol/corticosterone
release from human and rat adrenal cells in vitro
(Gaillard et al. 2000). Thus, the possible pathogenic role
for leptin in sepsis may be linked to leptin-inducedhttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-13-0249
 2014 The authors
Printed in Great Britainsuppression of the HPA axis impairing the protective role
of the HPA axis in sepsis.
We hypothesised that leptin attenuates the HPA
axis response to sepsis. We investigated the direct effects
of leptin on the HPA axis response to acute lipopolysac-
charide (LPS) administration in rats, a model of the
neuroimmunological changes observed in sepsis in both
rodents and humans. Acute LPS administration increases
circulating levels of the cytokines IL1b, IL6 and TNFa
and up-regulates the HPA axis (Besedovsky et al. 1986,
Rivier et al. 1989, Takao et al. 1993, Csontos et al. 2010).
If leptin acts to exacerbate the pathophysiological
response to LPS, it would suggest a possible role for anti-
leptin therapy in high-risk septic patients.Materials and methods
Animals
Male Wistar rats (specifically pathogen free; Charles River,
Margate, UK) weighing 170–210 g and at 7 weeks of age
were maintained in groups of four under controlled
temperature (21G1 8C) and light (12 h light:12 h darkness
cycle; lights on at 0700 h) with access to food (RM1 diet,
Special Diet Services Ltd, Witham, Essex, UK) and water
and were allowed to feed ad libitum. They were handled
daily for 2 weeks before the study. All animal procedures
conducted were approved by the British Home Office
under the Animals (Scientific Procedures) Act 1986.Materials
LPS from Escherichia coli was supplied by Sigma–Aldrich
Ltd. Recombinant rat leptin was supplied by R&D Systems
(Abingdon, UK).Study design
Leptin has been shown to significantly reduce basal
plasma corticosterone levels, 3–4 h after administration
(Clark et al. 2008). Plasma stress hormone levels peak at
1–2 h after i.p. LPS administration, at doses ranging from
10.5 to 250 mg/kg (Takemura et al. 1997, Gaillard et al.
2000, Tolchard et al. 2009), to levels comparable with
those observed in septic rats (Carlson et al. 2007). Rats
(nZ10/group) were administered with either 100 ml
vehicle (saline) or 2 mg/kg recombinant rat leptin intra-
peritoneally, a dose previously shown to suppress the HPA
axis response to acute restraint stress (Heiman et al. 1997)
and to activate regions of the brain involved in thePublished by Bioscientifica Ltd
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2 h, rats received a second i.p. injection of either 100 ml
vehicle (saline) or 25 mg/kg LPS, a dose that induces a
significant, albeit reversible, increase in HPA activity
(Huang et al. 1998). All rats were killed by decapitation
2 h after the second injection and trunk blood was
immediately collected into plastic potassium-EDTA tubes
(1.6 mg EDTA/mm of blood). Plasma was separated by
centrifugation for 10 min at 2000 r.p.m. (Boeco Centrifuge
S-8, Boeco, Hamburg, Germany) and stored at K70 8C for
measurement of ACTH, corticosterone, leptin and IL1b
concentrations.Plasma hormone measurements
Plasma ACTH levels were measured by IRMA (DiaSorin,
Stillwater, MN, USA); intra-assay variation was 3.5–4.8%
and inter-assay variation was 3.2–5.7%. Plasma cortico-
sterone levels were determined by enzyme immunoassay
(Cayman Chemical Company, Cambridge, UK); intra-
assay variation was 8% and inter-assay variation was 9.8%.
Plasma leptin levels were determined by ELISA (Crystal
Chem, Inc., Downers Grove, IL, USA); both intra-assay and
inter-assay variations were%10%. Plasma IL1b levels were
determined by ELISA R&D Systems; intra-assay variation
was 3.9–8.8% and inter-assay variation was 4.1–5.7%. All
assays were performed according to the manufacturers’
instructions.Statistical analysis
All data are presented as meanGS.E.M. Groups were com-
pared using one-way ANOVA followed by Tukey’s post-hoc
test with GraphPad Prism version 5 (GraphPad Software,0
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Figure 1
The effect of leptin on LPS-stimulated increases in ACTH, corticosterone
and IL1b concentrations. Male Wistar rats were intraperitoneally injected
with 100 ml saline or 2 mg/kg leptin 2 h before being intraperitoneally
injected with 100 ml saline or 25 mg/kg LPS. Rats were decapitated 2 h
after LPS injection and plasma (A) ACTH, (B) corticosterone, (C) IL1b and
http://joe.endocrinology-journals.org
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Printed in Great BritainInc., La Jolla, CA, USA). In all cases, P!0.05 was considered
statistically significant.Results
Effect of leptin on the HPA axis response to LPS
At 2 h after administration, 25 mg/kg LPS significantly
increased plasma ACTH (674G217 pg/ml) and cortico-
sterone (381.8G32.6 ng/ml) levels (Fig. 1A and B).
Pre-treatment with 2 mg/kg leptin, 2 h before LPS admin-
istration, did not significantly influence the HPA axis
response to LPS (ACTH, 608G160 pg/ml; corticosterone,
403.3G59.2 ng/ml) (Fig. 1A and B). LPS did not affect
plasma leptin (23G1.09 ng/ml) levels (Fig. 1D) but did
significantly increase plasma IL1b (65.5G13.6 pg/ml)
levels (Fig. 1C) compared with untreated controls. Leptin
had no effect on basal (7.77G0.714 pg/ml) or LPS-
stimulated (68.8G15.5 pg/ml) plasma IL1b concen-
trations (Fig. 1C). As expected, plasma leptin levels were
significantly higher in rats that received leptin compared
with rats that did not receive leptin (Fig. 1D).Discussion
We aimed to investigate the effect of leptin on the
neuroendocrine response to LPS in the male Wistar rat.
Our studies suggest that peripheral leptin administration
does not affect the HPA axis or the cytokine response to
LPS-induced endotoxaemia.
Based on the evidence in the literature that LPS
activates the HPA axis at doses ranging from 10.5 to
250 mg/kg in rats, we initially carried out a dose–response
study investigating the effects of various doses of0
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(D) leptin concentrations were measured. Data are presented as meanG
S.E.M. one-way ANOVA. *P!0.05 vs saline; **P!0.01 vs saline; ***P!0.001
vs saline; $P!0.05 vs leptin; $$P!0.01 vs leptin; $$$P!0.001 vs leptin;
bbbP!0.001 vs LPS and nZ8–10.
Published by Bioscientifica Ltd
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221 :2 240LPS (10, 25, 100, 250 mg/kg) on HPA axis activation
(S Basharat, KG Murphy, SR Bloom, JC Buckingham &
CD John, 2012, unpublished observations). We found
25 mg/kg LPS to be the lowest dose that significantly
elevated plasma ACTH and corticosterone levels at the
pertinent time points in our model (nZ10). Others have
previously shown that our chosen dose of LPS induces a
strong but reversible stress response, as demonstrated by
the inhibition of 25 mg/kg LPS-induced fever by systemic
administration of a-MSH in rats (Huang et al. 1998).
Plasma ACTH and corticosterone levels measured 2 h after
i.p. LPS administration within the study by Huang and
colleagues were similar to those achieved in our study. We
measured IL1b as an early marker of sepsis in our model as
it is one of the cytokines most strongly associated with
sepsis and, in both human and experimental septic
models, has been shown to act as an ‘initiator’ cytokine
that stimulates a cytokine cascade, ultimately driving
many of the physiological changes seen in sepsis (Black-
well & Christman 1996). The plasma IL1b levels achieved
in our LPS-treated rats are similar to levels observed in
septic humans (Kurt et al. 2007, Sankar & Webster 2012)
and fall into the range of IL1b levels observed in animal
models of sepsis (Rodrı´guez-Wilhelmi et al. 2002). Our
chosen dose of leptin was the same as that used in the
study carried out by Heiman et al. (1997), which
demonstrates that leptin can blunt restraint stress-induced
HPA activation in mice 3–4 h after its administration. Our
study was designed to use the same time points but with a
different stressor (LPS), given that interpreting the contra-
dictory literature regarding the effects of leptin on the HPA
axis is difficult due to the variations in the time points
investigated, mode of plasma and tissue collection and
animal model used. Clark et al. (2008) also utilised the
same leptin dose and time point as our study. In contrast
to our finding, they found that leptin suppressed baseline
corticosterone levels, perhaps because their rats had
higher basal corticosterone levels (200 ng/ml compared
with 25 ng/ml in our study (Clark et al. 2008)), which may
perhaps reflect differences in housing or strain. It may be
difficult to detectably suppress corticosterone concen-
trations below relatively low basal levels. In our study,
2 mg/kg leptin induced circulating plasma leptin levels
well above those seen in obese rats (Beck & Richy 2009).
It is possible that investigating the effects of different
doses of LPS and leptin, and/or measuring HPA axis
activation at different time points might reveal effects of
leptin that we do not detect in this study. Conflicting
reports suggest that leptin can stimulate or suppress the
HPA axis in different contexts (Maffei et al. 1995, Heimanhttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-13-0249
 2014 The authors
Printed in Great Britainet al. 1997, Nishiyama et al. 1999, Jethwa et al. 2006) and
suggest that animal model, type of stressor and route
of leptin administration can greatly influence study
outcome. Evidence for the suppressive effects of leptin
on the HPA axis includes the ability of leptin to blunt the
stress-induced activation of the HPA axis in mice (Heiman
et al. 1997), inhibit CRH release from stimulated ex vivo rat
hypothalamic explants (Heiman et al. 1997) and attenuate
ACTH-stimulated cortisol release from adrenal cells in vitro
(Bornstein et al. 1997, Gaillard et al. 2000). The presence of
the leptin receptor (LEPR) in ACTH-producing cells of the
anterior pituitary gland (Zamorano et al. 1997) suggests
that they are targets of leptin signalling, though incu-
bation of primary rat pituitary cells with leptin does not
influence CRH-induced ACTH release (Heiman et al.
1997). Peripheral leptin administration to fasted mice
attenuates the fasting-induced activation of the HPA axis
as demonstrated by normalised plasma ACTH and
corticosterone levels comparable to those seen in fed
mice (Ahima et al. 1996), while systemic administration of
leptin in male Sprague–Dawley rats decreases baseline
plasma corticosterone levels (Clark et al. 2008).
However, under specific conditions, leptin can stimu-
late the HPA axis. I.c.v. administration of leptin has been
shown to increase Crh and CRH receptor (Crhr2) mRNA
expression in the rat hypothalamic paraventricular nucleus
and ventromedial nucleus (Nishiyama et al. 1999). Leptin
also stimulates CRH release from hypothalamic explants
(Costa et al. 1997, Raber et al. 1997, Jethwa et al. 2006) and
Jethwa et al. (2006) reported an acute stimulatory effect of
peripheral leptin on the HPA axis in rats.
Such variable findings stem from the absence of
uniformly designed and directly comparable in vivo
leptin-stress experiments. Most studies have focused on
the ability of leptin to influence the HPA response to mild
stressors, whereas our study has focused on the effects of
leptin on the HPA response to a powerful immunological
stressor. It is interesting to note thatwhile different stressor
types, e.g. head trauma (Ott et al. 1987), stroke (Kang et al.
2008), autoimmune diseases (Hu et al. 1993) and psycho-
logical stress (Connor & Leonard 1998), ultimately activate
the HPA axis via a convergence at the hypothalamus to
precipitate the CRH–ACTH–glucocorticoid cascade,
there is surprisingly little overlap in the sets of genes
within the brain that are induced/repressed by severe
immunological stress compared with mild psychological
stressors such as restraint stress (Reyes et al. 2003).
Furthermore, in addition to the convergent effect at the
hypothalamus, LPS can act directly at the pituitary gland
to stimulate the inter-pituitary release of IL6, whichPublished by Bioscientifica Ltd
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2001, Watanobe & Yoneda 2003), and also within the
adrenal cortex (Andreis et al. 1991, Pournajafi Nazarloo
et al. 2003, Mohn et al. 2011). Leptin could feasibly reduce
adrenal gland sensitivity to ACTH stimulation, though
correlation analyses of plasma ACTH and corticosterone
concentrations in our animals indicate a moderate
positive correlation, suggesting that there is not a marked
reduction in ACTH sensitivity at the adrenal gland.
Therefore, the fact that LPS i) induces a different
activational response within the brain compared with
mild stressors and ii) activates the HPA axis at multiple
levels may provide an explanation as to why leptin failed
to attenuate the LPS-induced HPA response.
In conclusion, our findings show that an acute dose of
2 mg/kg leptin fails to influence HPA function or IL1b
secretion, 4 h after injection, in a rat model of acute
25 mg/kg LPS-induced sepsis. This suggests that leptin may
not to be involved in the acute-phase response to bacterial
infection in rats.Declaration of interest
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